Active Ingredient History
Tislelizumab, sold under the brand name Tevimbra among others, is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2. It is designed to bind less to Fc gamma receptors. It is being developed by BeiGene. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Angiogenesis Inhibitors (Phase 2)
Antineoplastic Agents (Phase 1/Phase 2)
Antineoplastic Agents, Immunological (Phase 2)
Anus Neoplasms (Phase 1)
Apoptosis (Phase 2)
Ascites (Phase 1)
Bevacizumab (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Capecitabine (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Chemoradiotherapy (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Colorectal Neoplasms, Hereditary Nonpolyposis (Early Phase 1)
Dendritic Cells (Phase 2)
Digestive System Neoplasms (Phase 2)
DNA Mismatch Repair (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 3)
Electroconvulsive Therapy (Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Epirubicin (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 3)
Gallbladder Neoplasms (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hodgkin Disease (Phase 3)
Immune Checkpoint Inhibitors (Phase 3)
Immunotherapy (Phase 2)
Intestinal Neoplasms (Phase 1/Phase 2)
Kidney Neoplasms (Phase 2)
Killer Cells, Natural (Phase 2)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 1)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 4)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasms (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteosarcoma (Early Phase 1)
Ovarian Neoplasms (Phase 2)
Oxaliplatin (Phase 2)
Pancreatic Neoplasms (Phase 2)
Patient Reported Outcome Measures (Phase 2)
Prostatic Neoplasms (Phase 2)
Radiation (Phase 2)
Radiation Oncology (Phase 2)
Radiotherapy (Phase 2)
Rectal Neoplasms (Phase 3)
Recurrence (Phase 3)
Safety (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 3)
Survival (Phase 2)
Testicular Neoplasms (Phase 1)
Thymoma (Phase 1)
Thyroid Carcinoma, Anaplastic (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 2)
Transplantation (Phase 3)
Triple Negative Breast Neoplasms (Phase 2)
Tumor Escape (Phase 2)
Urinary Bladder Diseases (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 4)
Urogenital Neoplasms (Phase 1/Phase 2)
Urologic Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue